Scholar Rock Holding Corporation
SRRK
Rang in Aktien
#3411
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Aktienkurs
$41.48
Marktkapitalisierung
$5.05B
Veränderung (1 Tag)
3.07%
Veränderung (1 Jahr)
48.55%
Land
US
Handel Scholar Rock Holding Corporation (SRRK)
Kategorie
Healthcare
P/B-Verhältnis für Scholar Rock Holding Corporation (SRRK)
P/B-Verhältnis zum October 2026 TTM: 20.38
Laut den neuesten Finanzberichten und dem Aktienkurs von Scholar Rock Holding Corporation beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 20.38. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 6.34.
P/B-Verlauf für Scholar Rock Holding Corporation von 2016 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 20.38 | 74.04% |
| 2024 | 11.71 | 84.56% |
| 2023 | 6.34 | 205.93% |
| 2022 | 2.07 | -60.88% |
| 2021 | 5.30 | -7.34% |
| 2020 | 5.72 | 77.92% |
| 2019 | 3.21 | -4.68% |
| 2018 | 3.37 | -165.04% |
| 2017 | -5.19 | -43.90% |
| 2016 | -9.24 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | -69.33% |
US
|
|
| 13.2547 | -34.96% |
US
|
|
| 4.208 | -79.35% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -69.67% |
NL
|
